Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis
出版年份 2017 全文链接
标题
Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 114, Issue 7, Pages E1072-E1080
出版商
Proceedings of the National Academy of Sciences
发表日期
2017-01-31
DOI
10.1073/pnas.1613091114
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
- (2016) Cristian Massacesi et al. OncoTargets and Therapy
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
- (2015) S. Picaud et al. CANCER RESEARCH
- Discovery of Chemical Inhibitors of Human Bromodomains
- (2015) Guangtao Zhang et al. CHEMICAL REVIEWS
- Fragment-Based Drug Discovery of 2-Thiazolidinones as BRD4 Inhibitors: 2. Structure-Based Optimization
- (2015) Lele Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors
- (2015) Xu Ran et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
- (2015) Timothy J. Stuhlmiller et al. Cell Reports
- Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer
- (2014) Jian Shi et al. CANCER CELL
- Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression
- (2014) Mar Gacias et al. CHEMISTRY & BIOLOGY
- A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis
- (2014) Shweta Joshi et al. MOLECULAR CANCER RESEARCH
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Rac2 Controls Tumor Growth, Metastasis and M1-M2 Macrophage Differentiation In Vivo
- (2014) Shweta Joshi et al. PLoS One
- The Commonly Used PI3-Kinase Probe LY294002 Is an Inhibitor of BET Bromodomains
- (2013) Antje Dittmann et al. ACS Chemical Biology
- BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses
- (2013) A. C. Belkina et al. JOURNAL OF IMMUNOLOGY
- Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors
- (2013) Guillermo A. Morales et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains
- (2013) Guangtao Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
- (2013) Anastasia Wyce et al. PLoS One
- Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
- (2013) Alexandre Puissant et al. Cancer Discovery
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Bromodomain 4 activation predicts breast cancer survival
- (2008) N. P. S. Crawford et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started